Enveric completes drug absorption studies for EB-003 candidate

Enveric Biosciences (NASDAQ:ENVB) reported positive preclinical results for its non-hallucinogenic psychiatric drug candidate, EB-003. The company's studies showed strong absorption, low protein binding, and stability against liver enzymes, supporting its therapeutic profile. EB-003 aims to treat psychiatric conditions without hallucinogenic effects. Shares were down 6.25% premarket at $1.35.

Enveric Biosciences reported positive in vitro ADMET results for EB-003, supporting progress toward a first-in-human trial. The company aims to advance the drug candidate with a planned IND filing.

Enveric Biosciences (NASDAQ: ENVB) reported Q2 2026 results and a corporate update. The company said EB-003 IND-enabling work advanced, including genotoxicity studies, and preclinical assays suggested a non-hallucinogenic and non-photoreactive profile. Enveric also received USPTO patent approvals and raised about $5.0M gross in a private placement plus $1.5M from warrant exercises. Net loss was $3.0M, cash $8.3M.

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: ● Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003

TechnipFMC (FTI) signed a memorandum of understanding with BP to supply high-pressure subsea production systems for BP's future developments in the U.S. Gulf. FTI's stock rose 1.6% on the news. The agreement establishes a framework for future collaboration.

TD Cowen kept its Hold rating on Moderna (MRNA) with a $90 price target, implying a 62.8% downside from the Oct 20 close. The firm cited positive clinical developments and resilient revenue projections for Moderna's COVID-19 and INT franchises.